nubeqa
bayer ag - darolutamide - neoplasmele prostatice, rezistent la castrare - terapia endocrină - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.
bimatoprost pharmathen 0,1 mg/ml
pharmathen s.a. - grecia - bimatoprostum - pic. oft., sol. - 0,1mg/ml - antiglaucomatoase si miotice analogi de prostaglandine
bimatoprost pharmathen 0,3 mg/ml
pharmathen s.a. - grecia - bimatoprostum - pic. oft., sol. - 0,3mg/ml - antiglaucomatoase si miotice analogi de prostaglandine
thiopental sodic panpharma 1 g
panpharma - franta - thiopentalum - pulb. pt. sol. inj. - 1g - anestezice generale barbiturice
thiopental sodic panpharma 500 mg
panpharma - franta - thiopentalum - pulb. pt. sol. inj. - 500mg - anestezice generale barbiturice
bupivacaina spinal heavy panpharma 5 mg/ml
panpharma gmbh - germania - bupivacainum - sol. inj. - 5mg/ml - anestezice locale amide
cefuroxima panpharma 750 mg
panpharma - franta - cefuroximum - pulb. pt. susp. inj. i.m./sol. inj. i.v. - 750mg - alte antibiotice betalactamice cefalosporine de generatia a ii-a
cefuroxima panpharma 1,5 g
panpharma - franta - cefuroximum - pulb. pt. sol. perf. i.v. - 1,5g - alte antibiotice betalactamice cefalosporine de generatia a ii-a
hidrocortizon panpharma 100 mg
panpharma - franta - hydrocortisonum - pulb+solv. pt. sol. inj./perf. - 100mg - corticosteroizi sistemici glucocorticoizi
budesonide/formoterol teva pharma b.v.
teva pharma b.v. - budesonide, formoterol - astm - medicamente pentru afecțiuni obstructive ale căilor respiratorii, - budesonidă / formoterol teva pharma b. este indicat numai la adulți cu vârsta de 18 ani și peste. asthmabudesonide/formoterol teva pharma b. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.